Antiretroviral (ARV) Agents Market Registers Strong Growth as Efforts to Curb Human Immunodeficiency Virus (HIV) Escalates
04 Nov 2021
AcquisitionCollaborate
Growing Popularity of Antiretroviral Therapy (ART) as a Long-Acting Suppression to Push Antiretroviral Agents Sales
The latest research report by Fact.MR presents an in-depth analysis of the antiretroviral (ARV) agents market size, growth drivers, restraints and opportunities. It also studies latest trends affecting the demand across leading segments in terms of drug type, distribution channel and region
Fact.MR – A Market Research and Competitive Intelligence Provider: As per Fact.MR, the antiretroviral (ARV) agents market is projected to register a healthy compound annual growth rate (CAGR) between 2021 and 2031.
The market is driven by rising prevalence of viral infections such as human immunodeficiency virus (HIV), increasing investments in research and development (R&D), and surging drug launches and approvals.
HIV continues to be a major global health issue, having claimed 36.3 million lives so far. According to the World Health Organization (WHO), there were around 37.7 million people living with HIV at the end of 2020. Furthermore, nearly 680,000 people died from HIV-related causes while 1.5 Mn acquired it during 2020.
There is no proper cure for HIV infection but it can be managed and suppressed by consuming antiretroviral agents or drugs. Antiretroviral agents are highly effective in suppressing viral replication within a person's body and help the immune system to regain its strength and capacity.
Growing awareness among people regarding HIV is expected to boost the sales of antiretroviral agents. If HIV is not treated on time, it can lead to acquired immunodeficiency syndrome (AIDS). Hence, people have increased the consumption of antiretroviral drugs to counter this transition of HIV.
Governments and other health organizations such as WHO are playing a crucial role in tackling the global burden of HIV infections. Various awareness programs and platforms are being launched to educate people about HIV and its treatments. This will also provide the additional thrust to the sales of antiretroviral agents.
Request a report sample to gain compressive insights at
As per Fact.MR, antiretroviral therapy is anticipated to remain the most lucrative application for antiretroviral agents. Antiretroviral therapy is a combination of several medicines which is used to control HIV infection.
Regionally, North America dominates the antiretroviral agents market, owing to the increasing investments in R&D activities, high prevalence of HIV cases, and strong presence of leading market players.
Within North America, the U.S. is expected to remain the most lucrative market for antiretroviral agents. According to the Centers for Disease Control and Prevention (CDC), an estimated 1,189,700 people in the U.S. had HIV at the end of 2019.
“Rising emphasis on research and development (R&D) activities to counter and curb the prevalence of HIV will create lucrative growth opportunities for the market during the forecast period. Key players are leveraging various strategies such as new product launches and approvals to keep pace with the rising demand for reducing the global HIV burden. Moreover, increasing government support will bode well for the market,” says the Fact.MR analyst.
Key Takeaways from Antiretroviral (ARV) Agents Market Survey
The U.S. will retain its dominance in antiretroviral agents market on the back of strong presence of leading biopharmaceutical companies, rising incidence of chronic diseases, and continuous advancement in medical research.
Owing to the rising product launches and approvals, presence of key players and increasing R&D for developing effective treatments against infectious diseases, Europe is slated to exhibit strong growth during the forecast period.
Multi-class combination products segment is likely to emerge as the most effective treatment for controlling HIV infection.
Hospital pharmacies is expected to emerge as primary end-user with the increase in the sales of antiretroviral products.
Key Drivers
Rising prevalence of chronic diseases such as HIV will propel the demand for antiretroviral agents.
Growing awareness among people regarding diagnosis and treatment of HIV diseases is acting as a catalyst for the growth of antiretroviral agents’ market.
Unprecedented outbreak of COVID-19 pandemic positively impacted the antiretroviral agents market as demand for antiviral medicines such as Remdesivir and Favipiravir surged
Key Restraints
Side effects associated with antiretroviral agents might restrict the growth in the market.
Lack of availability and penetration of antiretroviral drugs across under developed countries such as Africa will also limit the sales.
Ask Your Antiretroviral (ARV) Agents Market Related Questions & Get Customized Reports
Competitive Landscape
Key players operating in the antiretroviral (ARV) agents market are focusing on the developing novel products at affordable prices. They have adopted various strategies such as mergers, acquisitions, drug approvals, awareness campaigns, expansions and collaborations to gain competitive edge in the market.
For instance,
In June 2021, Gilead Sciences, Inc. submits new drug new drug application (NDA) to the U.S. FDA seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in people with limited therapy option. Lenacapavir is being developed in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients who fail to respond to other therapies
In December 2020, ViiV Healthcare, the global specialist HIV company annouced the authorization of Vocabria (cabotegravir injection and tablets) in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union, for the treatment of HIV-1 infection in adults who are virologically suppressed.
In July 2020, the U.S. Food and Drug Administration (FDA) approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be treated with other therapies.
Some of the leading manufacturers and suppliers of antiretroviral (ARV) agents profiled by Fact.MR are:
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Pfizer
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Others
More Insights on the Global Antiretroviral (ARV) Agents Sales Outlook
Fact.MR provides an unbiased analysis of antiretroviral (ARV) agents market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for antiretroviral (ARV) agents with a detailed segmentation on the basis of:
Drug Type
Nucleoside Reverse Transcriptase Inhibitors
Multi-Class Combination Products
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Entry Inhibitors — CCR5 Co-Receptor Antagonist
Fusion Inhibitors and Others
Distribution channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)
Key Questions Covered in the Antiretroviral (ARV) Agents Market Outlook Report
The report offers insight into antiretroviral (ARV) agents demand outlook for 2021-2031
The market study also highlights projected sales growth for antiretroviral (ARV) agents market between 2021 and 2031
Antiretroviral (ARV) agents market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
Antiretroviral (ARV) agents market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
HIV-associated Nephropathy Treatment Market- Due to the availability of the only such therapy type that is being utilized on a global level to cure severe health issues, the global market for HIV-associated nephropathy treatment is predicted to develop significantly and continuously over the forecast period. The majority of the increase is due to an increase in HIV diagnoses, which is largely seen in black individuals, indicating a genetic element in HIV-associated nephropathy treatment, but HIV also affects those who come into touch with it. Because it is a treatment market for a dangerous disease, it is projected to grow as the number of HIVAN cases rises.
Pediatric HIV Infection Treatment Market- The growing frequency of HIV infection in children is driving the market for pediatric HIV infection treatment. During the projected period, the market would be driven by the active involvement of national and international government organizations in promoting HIV infection therapy drug research. Furthermore, expanding private-public partnerships for research and development efforts, as well as rising healthcare expenditure, are propelling the pediatric HIV infection treatment market forward.
Cox 2 Inhibitors Market- Non-steroidal anti-inflammatory drugs (NSAIDs) such as Cox 2 Inhibitors are a form of NSAID. These medications work by reducing the generation of prostaglandins. One of the primary factors driving the growth of the cox 2 inhibitors market is the increased acceptance rate of cox 2 inhibitors, such as aspirin pain relievers. The market for cox 2 inhibitors is predicted to develop as the prevalence of chronic diseases such as rheumatoid arthritis, osteoarthritis, and other diseases rises. Increased awareness of physical activities may result in sports injuries, which will likely increase the cox 2 inhibitors market.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.